Total Results: 363

Trump Executive Order Draft On Drug Prices Would Decrease Regulations, Take Steps To Increase Competition

KHN Morning Briefing

CQ Roll Call reports that a draft document indicates that the Trump administration leaning toward a roll back of regulations to foster faster drug approvals and promoting competition and new payment models for federal insurance programs. In other pharmaceutical industry news, Mylan shareholders reject the EpiPen maker’s executive pay policy but re-elect its board.

EpiPen Maker Reportedly Offered States Discounts If They Cut Down Competition

KHN Morning Briefing

Stat reports that Mylan made the rebates conditional on states requiring that competitors’ products get special requests by clinicians to be covered by Medicaid. In other news, the Food and Drug Administration says it will hold a hearing on efforts by drugmakers to impede competition, and an Australian drug company that is linked to a U.S. congressman gets approval for U.S. trials.

Cutting Medicaid Funding In Midst Of Opioid Crisis Would Be ‘Catastrophic,’ Advocates Warn

KHN Morning Briefing

“It would essentially write off a generation,” said Dr. Shawn Ryan, president of BrightView Health, a network of drug treatment clinics in Cincinnati. In other news on the opioid crisis, Missouri becomes the latest state to file suit against drugmaker Purdue Pharma, one in four people on Medicaid received opioids in 2015, and a county reveals its plan to curtail the epidemic.

Trump’s Working Group On Drug Prices Catering To Pharma’s Wish List

KHN Morning Briefing

Despite promising action to reel in an industry that he said was “getting away with murder,” President Donald Trump and his administration’s working group on high prescription drug costs is leaning toward policy recommendations backed by pharmaceutical companies.